insights_auto
Sebab 2359 menurun 2.19%?
Terokai Dengan Lebih Terperincichevron_right
2359:HKG
WuXi AppTec Ord Shs H
HK$196.20
arrow_downward
-2.19%(-4.40) 1H
16 Okt, 4:08:14 PTG GMT+8 · HKD
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk 2359...
Buka
HK$203.80
Tinggi
HK$209.00
Rendah
HK$185.00
Permodalan Pasaran
544.52B
Purata volum
3.91J
Volum
10.16J
Dividen
1.22%
Dividen suku tahunan
HK$0.60
Tarikh tanpa dividen
4 Sep 2026
Nisbah H/P
23.98
tgi 52 mgu
HK$219.20
rdh 52 mgu
HK$96.70
EPS
HK$8.18
Bilangan pekerja
36K
Buka
HK$203.80
Tinggi
HK$209.00
Rendah
HK$185.00
Permodalan Pasaran
544.52B
Purata volum
3.91J
Volum
10.16J
Dividen
1.22%
Dividen suku tahunan
HK$0.60
Tarikh tanpa dividen
4 Sep 2026
Nisbah H/P
23.98
tgi 52 mgu
HK$219.20
rdh 52 mgu
HK$96.70
EPS
HK$8.18
Bilangan pekerja
36K
Cerita berita
Daripada sumber web dan rakan kongsi berita
ad-hoc-news.de
·
18 jam lalu
Morgan Stanley keeps target for WuXi AppTec stock at HKD 207.40
ad-hoc-news.de
·
1 hari lalu
Morgan Stanley backs 800-ton expansion for WuXi AppTec stock
ad-hoc-news.de
·
2 hari lalu
Morgan Stanley keeps HKD 207.40 target for WuXi AppTec stock
ad-hoc-news.de
·
2 hari lalu
Huaxi Securities maintains Buy for WuXi AppTec stock
Profil
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe.
Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
Perihal WuXi AppTec Ord Shs H